Home
Team
Russell Hirsch
David Schnell
Lisa Potocsnak
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News

Prospect Venture Partners

Home
Team
Russell Hirsch
David Schnell
Lisa Potocsnak
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News
David Schnell
February 5, 2018

February 5, 2018 - NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)

David Schnell
February 5, 2018

Source: http://www.ngmbio.com/media/press-releases/020518/

Newer PostMarch 12, 2018 - NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of Data At The International Liver Congress 2018
Older PostJanuary 3, 2018 - Insmed Announces Additional Data from ALIS Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC

Contact Prospect
Venture Partners:

Address:
525 University Ave., Suite 1350
Palo Alto, CA 94301

Phone:
(650) 327-8800

Prospect Ventures Funds:
Prospect Venture Partners I
Prospect Venture Partners II
Prospect Venture Partners III

 Connect with Prospect Ventures:
 Prospect Ventures on LinkedIn
 Prospect Ventures on Crunchbase
 Prospect Ventures on Bloomberg
 Prospect Ventures on CB Insights
 Prospect Ventures on Palico
 Prospect Ventures on Index.co
 Prospect Bio Ventures

Back to Top

© 2018 - Prospect Venture Partners.. All Rights Reserved
No content on this site may be republished or reprinted without written permission from Prospect Venture Partners